Cargando…

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension

OBJECTIVES/SPECIFIC AIMS: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). METHODS/STUDY POPULATION: BACKGROUND: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of nOH by replenishing NE levels. Central NE effects are...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonell, Katherine, Shibao, Cyndya, Biaggioni, Italo, Robertson, David, Claassen, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2018
Materias:	Basic/Translational Science/Team Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808185/ http://dx.doi.org/10.1017/cts.2018.158

Ejemplares similares

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
por: Biaggioni, Italo, et al.
Publicado: (2015)

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
por: Kaufmann, Horacio, et al.
Publicado: (2014)

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
por: Kaufmann, Horacio, et al.
Publicado: (2021)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension
por: Castro, Robert Alexander, et al.
Publicado: (2023)

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus
por: Vernino, Steven, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)

Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension
por: Grijalva, Carlos G., et al.
Publicado: (2017)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
por: Goodman, Brent P., et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension
por: Hewitt, L. Arthur, et al.
Publicado: (2021)

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
por: Hauser, Robert A., et al.
Publicado: (2022)

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension
por: Vernino, Steven, et al.
Publicado: (2017)

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report
por: Ho, Annie H., et al.
Publicado: (2020)

Impaired parasympathetic function in long-COVID postural orthostatic tachycardia syndrome – a case-control study
por: Rigo, Stefano, et al.
Publicado: (2023)

Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management
por: Metzler, Manuela, et al.
Publicado: (2012)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa
por: François, Clément, et al.
Publicado: (2022)

2516 Ultra-low Na18F tracer dosing for preclinical skeletal imaging enables new concepts in digital PET/CT
por: Menendez, Maria I., et al.
Publicado: (2018)

2216 Characterizing physician trust and healthcare-based discrimination among long-term HIV viral trajectory groups in Washington, DC
por: Michel, Katherine G., et al.
Publicado: (2018)

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
por: Gibbons, Christopher H., et al.
Publicado: (2017)

2128 Using real-time functional magnetic resonance imaging (fMRI) neurofeedback as a tool for demonstrating therapeutic efficacy in cognitive behavioral therapy
por: Dickerson, Kathryn, et al.
Publicado: (2018)

Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers
por: Claassen, Daniel O., et al.
Publicado: (2018)

2325 Targeting isoform-specific PI3 kinase signaling for treatment of cutaneous T cell lymphoma
por: Raychaudhuri, Suravi, et al.
Publicado: (2018)

3293 Region Specific Dysregulation of Dopaminergic Signaling in Mice Displaying Excessive Over-Grooming
por: Foster, Daniel, et al.
Publicado: (2019)

2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
por: D’Souza, Julia, et al.
Publicado: (2018)

2243 Perceptions of translational science among faculty researchers: A survey to inform the efforts of a multidisciplinary education and research program
por: Devi, Gayathri, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jusgqmtqsi1p3ervjvtqv68bs8